{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Vinke JSJ"],"pubmed_abstract":["<h4>Background</h4>Kidney transplant recipients (KTRs) have an impaired immune response after vaccination against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Iron deficiency (ID) may adversely affect immunity and vaccine efficacy. We aimed to investigate whether ferric carboxymaltose (FCM) treatment improves humoral and cellular responses after SARS-CoV-2 vaccination in iron-deficient KTRs.<h4>Methods</h4>We randomly assigned 48 iron-deficient KTRs to intravenous FCM (1-4 doses of 500mg with six-week intervals) or placebo. Co-primary endpoints were SARS-CoV-2-specific anti-Receptor Binding Domain (RBD) Immunoglobulin G (IgG) titers and T-lymphocyte reactivity against SARS-CoV-2 at four weeks after the second vaccination with mRNA-1273 or mRNA-BNT162b2.<h4>Results</h4>At f"],"journal":["Frontiers in immunology"],"pagination":["1017178"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9822258"],"repository":["biostudies-literature"],"pubmed_title":["Ferric carboxymaltose and SARS-CoV-2 vaccination-induced immunogenicity in kidney transplant recipients with iron deficiency: The COVAC-EFFECT randomized controlled trial."],"pmcid":["PMC9822258"],"pubmed_authors":["Altulea DHA","Eisenga MF","Niekolaas TM","Heiden MV","van Baarle D","Sanders JF","Steenhuis M","Abdulahad WH","Vinke JSJ","De Borst MH","Jagersma RL","Rispens T"],"additional_accession":[]},"is_claimable":false,"name":"Ferric carboxymaltose and SARS-CoV-2 vaccination-induced immunogenicity in kidney transplant recipients with iron deficiency: The COVAC-EFFECT randomized controlled trial.","description":"<h4>Background</h4>Kidney transplant recipients (KTRs) have an impaired immune response after vaccination against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Iron deficiency (ID) may adversely affect immunity and vaccine efficacy. We aimed to investigate whether ferric carboxymaltose (FCM) treatment improves humoral and cellular responses after SARS-CoV-2 vaccination in iron-deficient KTRs.<h4>Methods</h4>We randomly assigned 48 iron-deficient KTRs to intravenous FCM (1-4 doses of 500mg with six-week intervals) or placebo. Co-primary endpoints were SARS-CoV-2-specific anti-Receptor Binding Domain (RBD) Immunoglobulin G (IgG) titers and T-lymphocyte reactivity against SARS-CoV-2 at four weeks after the second vaccination with mRNA-1273 or mRNA-BNT162b2.<h4>Results</h4>At f","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-21T16:22:21.905Z","creation":"2025-04-21T16:22:21.905Z"},"accession":"S-EPMC9822258","cross_references":{"pubmed":["36618359"],"doi":["10.3389/fimmu.2022.1017178"]}}